Health
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark, September 03, 2025--Genmab A/S (Nasdaq: GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the safety and efficacy of investigational epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy administered in the outpatient setting in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy, including
About this update from Genmab A/s
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1301,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/5cbff553022e6f141f8d55fb2a43cc74"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UC6Xn0HA2R_VTZ4v7OZ5zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5cbff553022e6f141f8d55fb2a43cc74","width":960,"height":280},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lKWcUFB7hrWdgeaJw1rjIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5cbff553022e6f141f8d55fb2a43cc74","width":1200,"height":350}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting","length":170,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient setting","length":131,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Adverse event profile and efficacy were consistent with previously reported studies in R/R DLBCL patients","length":105,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Data also demonstrated 64.3% overall response rate with a complete response rate of 47.6% in patients treated with epcoritamab following one prior line of systemic DLBCL therapy","length":177,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":583,"olType":false},{"type":"text","content":"COPENHAGEN, Denmark, September 03, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the safety and efficacy of investigational epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy administered in the outpatient setting in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy, including at least one anti-CD20 monoclonal antibody-containing therapy. The study demonstrated the feasibility of treating and mon...